| Full text | |
| Author(s): |
de Torres Santos, Ana Paula
[1, 2]
;
Martins Silva, Vanessa Cristina
[1]
;
Mendes-Correa, Maria Cassia
[3]
;
Lemos, Marcilio Figueiredo
[1]
;
Malta, Fernanda de Mello
[4]
;
Ferraz Santana, Rubia Anita
[5]
;
Fernando Dastoli, Gregorio Tadeu
[5]
;
Duarte de Castro, Vanessa Fusco
[5]
;
Rebello Pinho, Joao Renato
[5, 2, 4]
;
Moreira, Regina Celia
[1]
Total Authors: 10
|
| Affiliation: | [1] Virol Ctr, Inst Adolfo Lutz, Lab Viral Hepatitis, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Hosp Clin, Fac Med, Div Lab Cent, Lab Imunol, Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Sch Med, LIM 52 Inst Trop Med, Dept Infect Dis, Sao Paulo, SP - Brazil
[4] Univ Sao Paulo, Sch Med, Lab Trop Gastroenterol & Hepatol Joao Queiroz & C, LIM Inst Trop Med 07, Dept Gastroenterol, Sao Paulo, SP - Brazil
[5] Hosp Israelita Albert Einstein, Albert Einstein Med Diagnost, Sao Paulo, SP - Brazil
Total Affiliations: 5
|
| Document type: | Journal article |
| Source: | INFECTION AND DRUG RESISTANCE; v. 14, p. 723-730, 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Purpose: Globally, it is estimated that 71 million people are chronically infected with hepatitis C, and 10-20% of these will develop cirrhosis and hepatocellular carcinoma. The development of new direct-acting antiviral (DAA) drugs has contributed to sustained virological response (SVR), eliminating the infection and achieving cure of chronic hepatitis C. However, treated patients can develop HCV resistance to DAAs, which can contribute to the failure of treatment. Here, we aimed to evaluate the prevalence and specific pattern of NS5A and NS5B resistance-associated substitutions (RAS) in samples from patients chronically infected with HCV genotype 3a at a public health laboratory, Instituto Adolfo Lutz, Sao Paulo, Brazil. Patients and Methods: Serum samples from the enrolled individuals were submitted to ``in-house{''} polymerase chain reaction amplification of NS5A and NS5B non-structural protein genes, which were then sequenced by Sanger method. Results: A total of 170 and 190 samples were amplified and analyzed for NS5A and NS5B, respectively. For NS5A, 20 (12.0%) samples showed some important RAS; 16 (9.0%) showed some type of substitution and 134 (79.0%) showed no polymorphism. No sample showed any RAS for NS5B. Conclusion: This study found important RAS in samples from naive chronic HCV patients in some areas from Sao Paulo. The most prevalent were A62S, A30K, and Y93H, which could indicate an increase in resistance to some DAAs used in HCV treatment. (AU) | |
| FAPESP's process: | 17/01809-9 - Characterizing HCV primary resistance mutations for direct acting antiviral drug (DAA) |
| Grantee: | Regina Célia Moreira |
| Support Opportunities: | Regular Research Grants |